HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Emergency Medicine125 papers

AApoAII amyloidosis

Last edited: 4/10/2026

Overview

AApoAII amyloidosis is a rare, inherited form of amyloidosis caused by mutations in the apolipoprotein AII (APOAI I) gene. It is characterized by the deposition of amyloid fibrils composed of apolipoprotein AII in various organs, leading to organ dysfunction.

Diagnosis

Management

  • Evinacumab is a novel therapeutic agent that inhibits angiopoietin-like protein 3 (ANGPTL3) and has demonstrated significant reductions in LDL-C, triglycerides, and HDL-C in patients with hypercholesterolemia 1.

    • Special Populations

    Key Recommendations

  • Evinacumab significantly reduces LDL-C by a mean difference of -33.123% (95% CI, -48.639% to -17.606%) 1. (Evidence: Strong)
  • Evinacumab significantly reduces triglycerides by a mean difference of -50.959% (95% CI, -56.555% to -45.362%) 1. (Evidence: Strong)
  • Evinacumab significantly reduces HDL-C by a mean difference of -12.773% 1. (Evidence: Strong)

    • References

    1 Jin M, Meng F, Yang W, Liang L, Wang H, Fu Z. Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis. Journal of cardiovascular pharmacology 2021. link 2 Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S et al.. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018. link

    Original source

    1. [1]
      Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis. — Jin M, Meng F, Yang W, Liang L, Wang H, Fu Z Journal of cardiovascular pharmacology (2021)
    2. [2]
      Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. — Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S et al. Gut (2018)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG